This preprint is under consideration at BioPsychoSocial Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Shota Noda
Panic Disorder Research Center, Warakukai Medical Corporation
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7376-7630
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Anxious-depressive attack (ADA) is a symptom complex that comprises sudden intense feelings of anxiety or depression, intrusive rumination of regretful memories or future worries, emotional distress due to painful thoughts, and coping behaviors to manage emotional distress. ADA has been observed transdiagnostically across various psychiatric disorders. Although the importance of ADA treatment has been indicated, a scale to measure the severity of ADA has not been developed. This study aimed to develop the Anxious-Depressive Attack Severity Scale (ADAS) for measuring the severity of ADA symptoms and examine its reliability and validity.
Methods: A total of 242 outpatients responded to a questionnaire and participated in an interview, which were designed to measure the severity of ADA, depression, anxiety, anxious depression, and social anxiety symptoms. Based on the diagnostic criteria for ADA, 54 patients were confirmed to have ADA and were included in the main study analyses.
Results: The results of the exploratory factor analysis showed that the ADAS had two factors: severity of ADA symptoms and ADA frequency and coping behaviors. McDonald's ωt coefficients were high for the overall scale and the first factor (ωt = .78 and ωt = .83, respectively) but low for the second factor (ωt = .49). The ADAS score was significantly positively correlated with clinical symptoms related to anxiety and depression.
Conclusion: The present study demonstrated that the ADAS had sufficient reliability and validity; however, internal consistency was insufficient for the second factor. Overall, the ADAS has potential to be a valuable tool for use in clinical trials of ADA.
Keywords
Anxious-Depressive Attack Severity Scale, Anxious-depressive attack, Anxious depression, Reliability, Validity
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 26 Feb, 2021
No community comments so far
Editorial decision: Major revision
On 26 Mar, 2021
Review #2 received
Received 25 Mar, 2021
Review #1 received
Received 10 Mar, 2021
Reviewer #2 agreed
On 28 Feb, 2021
Reviewer #1 agreed
On 23 Feb, 2021
Reviews received
Received 23 Feb, 2021
Reviewers invited
Invitations sent on 23 Feb, 2021
Editor assigned
On 21 Feb, 2021
Submission checks complete
On 21 Feb, 2021
Editor invited
On 21 Feb, 2021
First submitted
On 20 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Biophysics
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This preprint is under consideration at BioPsychoSocial Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Shota Noda
Panic Disorder Research Center, Warakukai Medical Corporation
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7376-7630
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 26 Feb, 2021
No community comments so far
Editorial decision: Major revision
On 26 Mar, 2021
Review #2 received
Received 25 Mar, 2021
Review #1 received
Received 10 Mar, 2021
Reviewer #2 agreed
On 28 Feb, 2021
Reviewer #1 agreed
On 23 Feb, 2021
Reviews received
Received 23 Feb, 2021
Reviewers invited
Invitations sent on 23 Feb, 2021
Editor assigned
On 21 Feb, 2021
Submission checks complete
On 21 Feb, 2021
Editor invited
On 21 Feb, 2021
First submitted
On 20 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Biophysics
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Anxious-depressive attack (ADA) is a symptom complex that comprises sudden intense feelings of anxiety or depression, intrusive rumination of regretful memories or future worries, emotional distress due to painful thoughts, and coping behaviors to manage emotional distress. ADA has been observed transdiagnostically across various psychiatric disorders. Although the importance of ADA treatment has been indicated, a scale to measure the severity of ADA has not been developed. This study aimed to develop the Anxious-Depressive Attack Severity Scale (ADAS) for measuring the severity of ADA symptoms and examine its reliability and validity.
Methods: A total of 242 outpatients responded to a questionnaire and participated in an interview, which were designed to measure the severity of ADA, depression, anxiety, anxious depression, and social anxiety symptoms. Based on the diagnostic criteria for ADA, 54 patients were confirmed to have ADA and were included in the main study analyses.
Results: The results of the exploratory factor analysis showed that the ADAS had two factors: severity of ADA symptoms and ADA frequency and coping behaviors. McDonald's ωt coefficients were high for the overall scale and the first factor (ωt = .78 and ωt = .83, respectively) but low for the second factor (ωt = .49). The ADAS score was significantly positively correlated with clinical symptoms related to anxiety and depression.
Conclusion: The present study demonstrated that the ADAS had sufficient reliability and validity; however, internal consistency was insufficient for the second factor. Overall, the ADAS has potential to be a valuable tool for use in clinical trials of ADA.
Loading...